There are multiple molecular mechanisms that mediate VB12 elevation, including the elevation of transporter proteins in neoplasms, massive release from hepatic reservoirs, decreased transcobalamin 2 production in liver disease or reduced transcobalamin 2 filtration in kidney disease [7]. This evidence concerns the gene TCN2 and kidney disorder.